Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
T cells that accompany allogeneic hematopoietic grafts for treating leukemia enhance engraftment and mediate the graft-versus-leukemia effect. Unfortunately, alloreactive T cells also cause graft-versus-host disease (GVHD). T cell depletion prevents GVHD but increases the risk of graft rejection and leukemic relapse. In human transplants, we show that donor-versus-recipient natural killer (NK)-cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD. In mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GVHD. NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NK cells, which act as important immune cells, are widely used for transplantation [82,83].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [82]
Citations
Cites
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Lanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells
Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J., & Emerson, S. G. (1999) · Science · doi:10.1126/science.285.5426.412 · Cited by 1,186
Self-citationAversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391702 · Cited by 1,168
Self-citationRole of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., & Velardi, A. (1999) · Blood · doi:10.1182/blood.v94.1.333.413a31_333_339 · Cited by 994
Self-citationHematopoietic Cell Transplantation
Forman, S. J., & Nakamura, R. (2015) · Blackwell Science Ltd eBooks · Cited by 659
Aversa, F., Tabilio, A., Terenzi, A., Velardi, A., Falzetti, F., Giannoni, C., Iacucci, R., Zei, T., Martelli, M., & Gambelunghe, C. (1994) · Blood · doi:10.1182/blood.v84.11.3948.bloodjournal84113948 · Cited by 576
Self-citationColonna, M., Borsellino, G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.12000 · Cited by 460
Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
Bachar-Lustig, E., Rachamim, N., Li, H.-W., Lan, F., & Reisner, Y. (1995) · Nature Medicine · doi:10.1038/nm1295-1268 · Cited by 322
Generation of Allospecific Natural Killer Cells by Stimulation Across a Polymorphism of HLA-C
Colonna, M., Brooks, E. G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Science · doi:10.1126/science.8493555 · Cited by 234
Research works printed but not linked: 3
- Valiante N. M., Parham P., Biol. Blood Marrow Transplant. 3, 229 (1997).
- A supplementary table and experimental procedures are available on Science Online at www.sciencemag.org/cgi/content/full/295/5562/2097/DC1.
- We thank A. Santucci for statistical analyses L. Romani for critical review of the manuscript and G. Boyd for her essential role in manuscript editing. Supported by grants from the Italian Association for Cancer Research the Italian Ministry of Research and the Italian Ministry of Health and by a translational research grant from the Leukemia and Lymphoma Society. W.D.S. is supported by NIH grant number HL03979.
Cited by
Items 901–1,000 of 1,002
Pollock, N. R., Harrison, G. F., & Norman, P. J. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.04.036 · Cited by 61
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors
Ghaedrahmati, F., Esmaeil, N., & Abbaspour, M. (2022) · 癌症:英文版 · doi:10.1002/cac2.12394 · Cited by 62
Hüber, C. M., Doisne, J., & Colucci, F. (2015) · European Journal of Immunology · doi:10.1002/eji.201445200 · Cited by 57
Stem cell transplantation for autoimmune diseases
Hügle, T., & Daikeler, T. D. (2010) · Haematologica · doi:10.3324/haematol.2009.017038 · Cited by 65
Microchip Screening Platform for Single Cell Assessment of NK Cell Cytotoxicity
Guldevall, K., Brandt, L., Forslund, E., Olofsson, K., Frisk, T. W., Olofsson, P. E., Gustafsson, K. U., Manneberg, O., Vanherberghen, B., Brismar, H., et al. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00119 · Cited by 57
“However, clinical trials using NK cells from haploidentical donors for cell therapy have shown encouraging results indicating that interindividual differences in NK cell recognition and responsiveness can be used to treat disease (7).”
BackgroundHoerster, K., Uhrberg, M., Wiek, C., Horn, P. A., Hanenberg, H., & Heinrichs, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.586168 · Cited by 63
Strategies for Dodging the Obstacles in CAR T Cell Therapy
Kozani, P. S., Kozani, P. S., Rahbarizadeh, F., & Nikkhoi, S. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.627549 · Cited by 60
Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors.
Koh, L., Rizzieri, D., & Chao, N. (2007) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2007.08.003 · Cited by 62
“The risk of day-100 RM has been reduced to below 20% in several ecent series of haploidentical transplant using reuced-intensity conditioning protocols [67,58,64].”
BackgroundSchroers, R., Hildebrandt, Y., Hasenkamp, J., Glass, B., Lieber, A., Wulf, G., & Piesche, M. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.03.010 · Cited by 60
Effect of splenectomy on antitumor immune system in mice.
Higashijima, J., Shimada, M., Chikakiyo, M., Miyatani, T., Yoshikawa, K., Nishioka, M., Iwata, T., & Kurita, N. (2009) · PubMed · Cited by 70
Antigen presentation in graft-vs-host disease
Shlomchik, W. D. (2003) · Experimental Hematology · doi:10.1016/j.exphem.2003.09.017 · Cited by 57
“Velardi analyzed the results of human haploidentical transplants and found that when NK cell alloreactivity was predicted (based on the HLA C and HLA B haplotypes of the donor and recipients), the incidence of GVHD was reduced [40].”
BackgroundSelf-citationCurrent status of haploidentical stem cell transplantation
Dey, B. R., & Spitzer, T. R. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06300.x · Cited by 58
“…of host antigen-presenting cells that are critical in the priming of alloreactive donor T cells and hence in the pathogenesis of GVHD; and (ii) NK cells that attack the host haematopoietic cells and spare the epithelial GVHD target tissues (Ruggeri et al, 1999, 2002; Shlomchik et al, 1999).”
BackgroundInfluentialCell Fate Reprogramming in the Era of Cancer Immunotherapy
Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56
Zhang, W., Zhao, Z., & Li, F. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.02.015 · Cited by 64
NK Cell Receptors as Tools in Cancer Immunotherapy
Sentman, C. L., Barber, M. A., Barber, A., & Zhang, T. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)95007-6 · Cited by 61
“…and hematopoietic stem cell transplantation (HSCT) (Chan et al., 2005; NK Cell Receptors in Cancer Immunotherapy Flores‐Villanueva et al., 2001; Giebel et al., 2005; Hiby et al., 2004; Martin et al., 2002; Momot et al., 2004; Nelson et al., 2004; Ruggeri et al., 2002; Warrington et al., 2001).”
NK Cells Lose Their Inhibition
Parham, P. (2004) · Science · doi:10.1126/science.1102025 · Cited by 56
Impola, U., Turpeinen, H., Alakulppi, N. S., Linjama, T., Volin, L., Niittyvuopio, R., Partanen, J., & Koskela, S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00405 · Cited by 56
Lehrnbecher, T., Koehl, U., Wittekindt, B., Bochennek, K., Tramsen, L., Klingebiel, T. E., & Chanock, S. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70071-8 · Cited by 61
Rusakiewicz, S., Perier, A., Semeraro, M., Pitt, J. M., von Strandmann, E. P., Reiners, K. S., Aspeslagh, S., Pipéroglou, C., Vely, F., Ivagnès, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1137418 · Cited by 64
An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia
Koerner, S., Andre, M. C., Leibold, J., Kousis, P. C., Kübler, A., Pal, M., Haen, S. P., Bühring, H.-J., Grosse-Hovest, L., Jung, G., et al. (2016) · Leukemia · doi:10.1038/leu.2016.194 · Cited by 56
Shimoni, A., Labopin, M., Lorentino, F., Lint, M. T. V., Koç, Y., Gülbaş, Z., Tischer, J., Bruno, B., Blaise, D., Pioltelli, P. E., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0170-5 · Cited by 56
“The Perugia group has clearly shown that in the context of extensive T cell depletion, high stem cell dose, and no post-transplant immune suppression, NK alloreactivity as predicted by the missing self model reduces the risk of relapse and markedly improve survival for patients with AML but not ALL [13, 14].”
Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes?
Vacca, P., Munari, E., Tumino, N., Moretta, F., Pietra, G., Vitale, M., Zotto, G. D., Mariotti, F. R., Mingari, M. C., & Moretta, L. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.11.004 · Cited by 58
“Notably, the size of the alloreactive NK subset was found to directly correlate with a more efficient anti-leukemia effect and with the survival probability [56–58].”
BackgroundShimoni, A., Labopin, M., Finke, J., Ciceri, F., Deconinck, É., Kröger, N. M., Gramatzki, M., Stelljes, M., Blaise, D., Stoelzel, F., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0251-3 · Cited by 56
Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies
Tanaka, J., & Miller, J. S. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100678 · Cited by 62
Next-generation cell therapies: the emerging role of CAR-NK cells
Başar, R., Daher, M., & Rezvani, K. (2020) · Hematology · doi:10.1182/hematology.2020002547 · Cited by 62
“A number of preclinical studies have shown that NK cells in the graft can target and kill host lymphohematopoietic cells that may participate in the rejection of donor cells.(27) Indeed, our clinical data confirm the persistence of adoptively transferred CAR-NK cells at low levels in patients for at least a year, desp…”
Advances in the understanding of acute graft‐versus‐host disease
Morris, E. S., & Hill, G. R. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06510.x · Cited by 60
“In this specific setting, donor NK cells recognise the absence of donor class I on recipient APC and leukaemia cells and eliminate both, reducing GVHD whilst mediating GVL respectively (Ruggeri et al, 2002).”
BackgroundAutologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
Nahi, H., Chrobok, M., Meinke, S., Gran, C., Marquardt, N., Afram, G., Sütlü, T., Gilljam, M., Stellan, B., Wagner, A. K., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100508 · Cited by 62
“Applicability was further supported by findings on the role of NK cells in haploidentical hematopoietic stem cell transplantation (HSCT).(9,10) The ‘‘off-the-shelf’’ applicability of allogeneic NK cells has recently further boosted an interest in their clinical use.”
ResultOff-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19
Lu, T., Ma, R., Dong, W., Teng, K., Kollath, D. S., Li, Z., Yi, J., Bustillos, C. G., Ma, S., Tian, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30216-8 · Cited by 60
Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness
Panagi, M., Pilavaki, P., Constantinidou, A., & Stylianopoulos, T. (2022) · Theranostics · doi:10.7150/thno.72800 · Cited by 61
“Clinical success of CAR-NK cell therapy has been initially demonstrated in hematological cancers [45, 46] and currently is being evaluated in solid malignancies including sarcoma (NCT02100891).”
BackgroundRea, A., Santana-Hernández, S., Villanueva, J., Sanvicente-García, M., Cabo, M., Suárez-Olmos, J., Quimis, F. G., Qin, M., Llorens, E., Blasco-Benito, S., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02103-z · Cited by 66
“…allogeneic NK cell therapies, including chimeric antigen receptor (CAR)-NK cells, have shown clinical benefits in certain hematological malignancies 1,2 , their clinical efficacy in solid tumors remains limited 3–5 , due to their inefficient homing and function in the tumor microenvironment (TME)…”
Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant
Velardi, A., Ruggeri, L., & Mancusi, A. (2012) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32835423c3 · Cited by 58
“alloreactive clones that kill recipient cryopreserved leukaemic cells ([6,7], reviewed in [2]).”
BackgroundResultSelf-citationCiurea, S. O., Saliba, R. M., Rondón, G., Pesoa, S., Cano, P., Fernández-Viña, M., Qureshi, S. R., Worth, L. L., McMannis, J., Kebriaei, P., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.189 · Cited by 55
Haploidentical SCT in children: an update and future perspectives
Lang, P., & Handgretinger, R. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.285 · Cited by 55
Genetics of graft-versus-host disease: The major histocompatibility complex
Petersdorf, E. W. (2012) · Blood Reviews · doi:10.1016/j.blre.2012.10.001 · Cited by 59
“mismatched haploidentical transplantation tested the ligand mismatch model.(118) In this model, KIR ligand mismatching was associated with”
NK cell-based cancer immunotherapy: from basic biology to clinical application
Li, Y., Yin, J., Li, T., Huang, S., Yan, H., Leavenworth, J. W., & Wang, X. (2015) · Science China Life Sciences · doi:10.1007/s11427-015-4970-9 · Cited by 60
Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma
Zhuang, L., Fulton, R., Rettman, P., Sayan, E., Coad, J., Al‐Shamkhani, A., & Khakoo, S. I. (2018) · Hepatology International · doi:10.1007/s12072-018-9909-3 · Cited by 59
“The immunotherapeutic importance of NK has best been shown in haplo-identical bone marrow transplantation in which mismatched NK cells exert a key role in killing residual leukemic blasts without causing graft-versus-host disease [2].”
BackgroundHarnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside
Woan, K. V., & Miller, J. S. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0404 · Cited by 55
Positive and negative regulation of Natural Killer cells: Therapeutic implications
Hallett, W. H. D., & Murphy, W. J. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.003 · Cited by 63
Alyea, E. P., DeAngelo, D. J., Molldrem, J. J., Pagel, J. M., Przepiorka, D., Sadelin, M., Young, J. W., Giralt, S., Bishop, M., & Riddell, S. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.05.005 · Cited by 62
“The allogeneic GVT effect is closely associated with donor T cells, although alloreactive NK cells [245] are also involved in anti-AML effects [246,247].”
BackgroundMorvan, M. G., David, G., Sébille, V., Perrin, A., Gagne, K., Willem, C., Kerdudou, N., Denis, L., Clémenceau, B., Folléa, G., et al. (2008) · European Journal of Immunology · doi:10.1002/eji.200838407 · Cited by 53
Differential activation of cord blood and peripheral blood natural killer cells by cytokines
Alnabhan, R., Madrigal, J. A., & Saudemont, A. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.08.003 · Cited by 56
What Is the Role for Donor Natural Killer Cells after Nonmyeloablative Conditioning?
Baron, F., Petersdorf, E. W., Gooley, T. A., Sandmaier, B. M., Malkki, M., Chauncey, T. R., Maloney, D. G., & Storb, R. F. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.01.018 · Cited by 54
“Based on experimental observations, the Perugia investigators proposed that all mature NK cells express at least 1 inhibitory receptor for self HLA, and thus the presence or absence of functional KIRs can be detected by HLA genotype [10,37].”
BackgroundResultInfluentialNatural Killer Cells: The Secret Weapon in Dendritic Cell Vaccination Strategies
van Elssen, C. H. M. J., Oth, T., Germeraad, W. T. V., Bos, G. M. J., & Vanderlocht, J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2302 · Cited by 62
At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies
Locatelli, F., Merli, P., & Rutella, S. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0613343 · Cited by 55
“phological CR [15, 20] and in children and young adults,”
BackgroundResultImmunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies
Shevtsov, M. A., & Multhoff, G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00492 · Cited by 57
“Adoptive transfer of autologous or allogeneic NK cells might be superior to the currently widely used donor lymphocyte infusion, which predominantly contain T lymphocytes, due to the fact that NK cells provide the first line of defense and generally mediate less graft-versus-host disease (GvHD) than T cells (10, 11).”
BackgroundHaspels, H. N., Rahman, M. A., Joseph, J. V., Navarro, A. G., & Chekenya, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01345 · Cited by 59
“Nevertheless, it is well established that KIR receptor–ligand mismatch mediates potent graft-versus-leukemia effect, improving the outcome of patients receiving haploidentical hematopoietic stem cell transplantation (24, 71), as well as play important roles in the cytolysis of solid tumor cells in vitro (42).”
BackgroundNK Cells in the Treatment of Hematological Malignancies
González, A. P., Villa-Álvarez, M., Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., & Gonzalez, S. R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101557 · Cited by 60
“In the haploidentical HSCT, NK cell-mediated alloreactivity may remarkably increase the survival of patients with AML who are devoid of HLA-I molecules that match donor-inhibitory KIR receptor (see below) [54,55].”
BackgroundExploiting Human NK Cells in Tumor Therapy
Vacca, P., Pietra, G., Tumino, N., Munari, E., Mingari, M. C., & Moretta, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03013 · Cited by 56
“In this transplantation setting, donor NK cells may express KIR that do not recognize any of the HLA-Cl-I alleles of the patient (44, 45).”
BackgroundKey Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation
Baumeister, S. H. C., Rambaldi, B., Shapiro, R. M., & Romee, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00191 · Cited by 59
“first established that a NK-cell alloreactivity of the donor toward recipient (based on KIR receptor-ligand mismatch in the GVL direction and presence of alloreactive clones against recipient targets) lowered the AML relapse risk in the context of ex vivo depleted haplo-HCT (72).”
BackgroundWeisdorf, D. J., Cooley, S., Wang, T., Trachtenberg, E., Vierra‐Green, C., Spellman, S. R., Sees, J. A., Spahn, A., Vogel, J., Fehniger, T. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001053 · Cited by 54
“evaluated 337 375 120 201 233 53 Median (range) 42 (3-98) 46 (5-97) 45 (2-98) .”
InfluentialDeciphering Natural Killer Cell Homeostasis
Pfefferle, A., Jacobs, B., Haroun-Izquierdo, A., Kveberg, L., Sohlberg, E., & Malmberg, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00812 · Cited by 63
“Whereas many studies did not find a beneficial effect of genetic KIR ligand mismatch, calculation of the functional dose of KIR ligand mismatched NK cells was associated with less relapse after NK cell therapy against AML (130–132).”
BackgroundWang, X., Lee, D. A., Wang, Y., Wang, L., Yao, Y., Lin, Z., Cheng, J., & Zhu, S. (2012) · Clinical & Experimental Immunology · doi:10.1111/cei.12034 · Cited by 54
Markel, G., Seidman, R., Stern‐Ginossar, N., Cohen-Sinai, T., Izhaki, O., Katz, G., Besser, M. J., Treves, A. J., Blumberg, R. S., Loewenthal, R., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.6062 · Cited by 53
“as NK cells (7, 8) or dendritic cells (9).”
BackgroundStangl, S., Wortmann, A., Gürtler, U., & Multhoff, G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.6270 · Cited by 53
“Discussion NK cells have been found to play a crucial role in the control of hematological malignancies (35).”
BackgroundZecca, M., Strocchio, L., Pagliara, D., Comoli, P., Bertaina, A., Giorgiani, G., Perotti, C. G., Corbella, F., Brescia, L. P., & Locatelli, F. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.01.015 · Cited by 53
Marín, D., Gabriel, I. H., Ahmad, S., Foroni, L., de Lavallade, H., Clark, R. E., O’Brien, S. J., Sergeant, R., Hedgley, C. A., Milojković, D., et al. (2011) · Leukemia · doi:10.1038/leu.2011.180 · Cited by 53
The haploidentical option for high-risk haematological malignancies
Aversa, F., Reisner, Y., & Martelli, M. F. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.07.004 · Cited by 53
Self-citationNatural Killer Cells: From Basic Research to Treatments
Vivier, É., & Ugolini, S. (2011) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00018 · Cited by 58
“…particular, retrospective studies of KIR/HLA mismatched stem cell transplantation in acute myeloid leukemia patients showed that the lack of KIR engagement on donor NK cells by patient MHC class I molecules was associated with a significant reduced risk for leukemia relapse (Ruggeri et al., 2002).”
Veuillen, C., Aurran, T., Castellano, R., Rey, J., Mallet, F., Orlanducci, F., Pouyet, L., Just‐Landi, S., Coso, D., Ivanov, V., et al. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9624-5 · Cited by 57
“Several clinical studies have shown that allogeneic natural killer (NK) cells play a key role in that GvL effect [14, 15].”
BackgroundPesce, S., Squillario, M., Greppi, M., Loiacono, F., Moretta, L., Moretta, A., Sivori, S., Castagnola, P., Barla, A., Candiani, S., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02360 · Cited by 55
“KIR/KIR-ligand mismatch between donor and recipient has been shown to be associated with lower rates of leukemia relapse and higher survival (63, 64), suggesting that, in the absence of KIR/KIR-ligand binding, “alloreactive” NK cells may eradicate residual leukemia cells.”
BackgroundZaghi, E., Calvi, M., Marcenaro, E., Mavilio, D., & di Vito, C. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0718-300r · Cited by 44
Kloeß, S., Oberschmidt, O., Dahlke, J., Vu, X., Neudoerfl, C., Kloos, A., Gardlowski, T., Matthies, N., Heuser, M., Meyer, J., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.247 · Cited by 53
“6,7 Infusion of irradiated (10 Gy dose) NK-92 cells was shown to be safe, with evidence of efficiency in patients with refractory hematologic malignancies who relapsed after autologous hematopoietic stem-cell transplantation.”
Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors
Chen, Z., Yang, Y., Liu, L. L., & Lundqvist, A. (2019) · Cancers · doi:10.3390/cancers11071040 · Cited by 53
“This suggests that NK cells may be particularly effective when transferred across HLA barriers [7,8].”
BackgroundDuault, C., Kumar, A., Khani, A. T., Lee, S. J., Yang, L., Huang, M., Hurtz, C., Manning, B. S., Ghoda, L. Y., McDonald, T., et al. (2021) · Blood · doi:10.1182/blood.2020009871 · Cited by 62
Moesta, A. K., Abi‐Rached, L., Norman, P. J., & Parham, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803401 · Cited by 54
“N atural killer cells are implicated in several functions: innate immunity to viral infection (1), recruitment of adaptive immunity (2, 3), immune surveillance for cancer (4), implantation during pregnancy (5, 6), and graft-vs-leukemia effects following hematopoietic stem cell transplantation (7, 8).”
BackgroundEyrich, M. K., Leiler, C., Lang, P., Schilbach, K., Schumm, M., Bader, P., Greil, J., Klingebiel, T. E., Handgretinger, R., NIETHAMMER, D., et al. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704158 · Cited by 58
Dupont, B., & Hsu, K. C. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.07.013 · Cited by 54
Tissue-Specific Homing and Expansion of Donor NK Cells in Allogeneic Bone Marrow Transplantation
Olson, J. A., Zeiser, R., Beilhack, A., Goldman, J. J., & Negrin, R. S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804268 · Cited by 58
Beck, R. C., Padival, M., Yeh, D., Ralston, J., Cooke, K. R., & Lowe, J. B. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.06.002 · Cited by 55
“In addition, data from haploidentical HSCT patients indicate that donor ‘‘alloreactive’’ NK cells, which lack MHC class I inhibitory signals because of KIR:MHC mismatch with recipient cells, may prolong survival in leukemia patients [38-40].”
Role of HLA in Hematopoietic Stem Cell Transplantation
Park, M., & Seo, J. J. (2012) · Bone Marrow Research · doi:10.1155/2012/680841 · Cited by 52
Skert, C., Damiani, D., Michelutti, A., Patriarca, F. F., Arpinati, M., Filì, C., Lucchi, P. P., Malagola, M., Bergonzi, C., Roccaro, A. M., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.80 · Cited by 52
Zhang, C., Todorov, I., Lin, C.-L. V., Atkinson, M. A., KANDEEL, F. R., Forman, S. J., & Zeng, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611101104 · Cited by 56
Current status of haploidentical stem cell transplantation for leukemia
Huang, X. (2008) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-1-27 · Cited by 57
“serve as a donor; 2) The ability to select the best of many potential donors on the basis of HLA mismatch, age, natural killer (NK) cell alloreactivity[ 7-9 ]; 3) Easy access to repeat donation of donor cells again, when donor-derived cellular therapy is needed for the treatment and/or prophylaxis of relapse, or for s…”
BackgroundNatural killer cells: The journey from puzzles in biology to treatment of cancer
Bodduluru, L. N., Kasala, E. R., Madhana, R. M., & Sriram, C. S. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.020 · Cited by 61
“that KIR mismatch was associated with better outcomes in leukemia [90].”
BackgroundDomogala, A., Madrigal, J. A., & Saudemont, A. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.02.008 · Cited by 52
“In a transplantation setting, alloreactive NK cells from the donor have demonstrated the ability to generate an immune response against leukemic cells and prevent graft rejection [1], whereas allogeneic NK cells alone have induced remission in high-risk patients without causing graft-versus-host disease [2].”
BackgroundWanquet, A., Bramanti, S., Harbi, S., Fürst, S., Legrand, F., Faucher, C., Granata, A., Calmels, B., Lemarié, C., Picard, C., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.11.042 · Cited by 52
Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response
Shembrey, C., Huntington, N. D., & Hollande, F. (2019) · Cancers · doi:10.3390/cancers11091217 · Cited by 56
“Whilst adoptive transfer of HLA-mismatched NK cells induces graft-versus-tumor effects, these cells do not contribute to dose-limiting graft-versus-host disease (GvHD) and may even play a protective role by dampening alloreactive T-cell responses [185,186].”
BackgroundSchetelig, J., Baldauf, H., Heidenreich, F., Massalski, C., Frank, S., Sauter, J., Stelljes, M., Ayuk, F. A., Bethge, W. A., Bug, G., et al. (2020) · Blood · doi:10.1182/blood.2019002887 · Cited by 57
The Role of Natural Killer Cells in Human Solid Organ and Tissue Transplantation
Villard, J. (2011) · Journal of Innate Immunity · doi:10.1159/000324400 · Cited by 52
Nguyen, S., Kuentz, M., Vernant, J.-P., Dhédin, N., Bories, D., Debré, P., & Vieillard, V. (2007) · Leukemia · doi:10.1038/sj.leu.2405041 · Cited by 56
Verheyden, S., Ferrone, S., Mulder, A., Claas, F., Schots, R., de Moerloose, B., Benoit, Y., & Demanet, C. (2008) · Cancer Immunology and Immunotherapy · doi:10.1007/s00262-008-0601-7 · Cited by 52
“Furthermore, we have compared the HLA class I allele expression level on myeloid and lymphoid leukemic cells, since NK cells have been shown to inhibit the growth of AML cells, but to have no detectable effect on that of acute lymphoid leukemic (ALL) cells [1, 2].”
BackgroundPost‐consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin‐2 in AML
Romero, A. I., Thorén, F. B., Aurelius, J., Askarieh, G., Brune, M. L., & Hellstrand, K. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02303.x · Cited by 61
Fully functional NK cells after unrelated cord blood transplantation
Béziat, V., Nguyen, S., Lapusan, S., Hervier, B., Dhédin, N., Bories, D., Uzunov, M., Boudifa, A., Trebeden‐Negre, H., Norol, F., et al. (2009) · Leukemia · doi:10.1038/leu.2008.343 · Cited by 60
Diversity of killer cell immunoglobulin-like receptor genes in Pacific Islands populations
Velickovic, M., Velickovic, Z., & Dunckley, H. (2006) · Immunogenetics · doi:10.1007/s00251-006-0124-3 · Cited by 52
“Recently, Ruggeri et al. (2002) reported that KIR ligand mismatch was protective against graft-vshost disease and graft rejection, and it increased overall survival.”
BackgroundImmune reconstitution after T-cell replete HLA-haploidentical transplantation
McCurdy, S. R., & Luznik, L. (2019) · Seminars in Hematology · doi:10.1053/j.seminhematol.2019.03.005 · Cited by 52
Targeting the innate immune system in pediatric and adult AML
Perzolli, A., Koedijk, J. B., Zwaan, C. M., & Heidenreich, O. T. (2024) · Leukemia · doi:10.1038/s41375-024-02217-7 · Cited by 60
“NK cell alloreactivity is triggered by the mismatch between killer-cell immunoglobulin-like receptors (KIRs) on donor NK cells and human leukocyte antigen (HLA) class I molecules on recipient cells [148].”
Progress and challenges in developing allogeneic cell therapies
Deuse, T., & Schrepfer, S. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.03.004 · Cited by 51
FLT3 inhibitors for the treatment of acute myeloid leukemia.
Wiernik, P. H. (2010) · PubMed · Cited by 51
Education of hyporesponsive NK cells by cytokines
Juelke, K., Killig, M., Thiel, A., Dong, J., & Romagnani, C. (2009) · European Journal of Immunology · doi:10.1002/eji.200939307 · Cited by 51
Nalle, S. C., Kwak, H. A., Edelblum, K. L., Joseph, N. E., Singh, G., Khramtsova, G. F., Mortenson, E. D., Savage, P. A., & Turner, J. R. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008941 · Cited by 54
“AlthoughNK cells have long been of interest in GVHD (24, 25), NK cells of donor origin, which reduce GVHD while enhancing graft antitumor activity (26–33), are the most well studied.”
Carvalho, A., Cunha, C., Ianni, M. D., Pitzurra, L., Aloisi, T., Falzetti, F., Carotti, A., Bistoni, F., Aversa, F., & Romani, L. R. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.28 · Cited by 51
Self-citationLevescot, A., Flamant, S., Basbous, S., Jacomet, F., Féraud, O., Bourgeois, E. A., Bonnet, M., Giraud, C., Roy, L., Barra, A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2797 · Cited by 55
Antigen-specific expansion and differentiation of natural killer cells by alloantigen stimulation
Nabekura, T., & Lanier, L. L. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20140798 · Cited by 54
“Article 2463 a survival advantage (Miller et al., 2005; Ruggeri et al., 2002, 2007).”
Natural killer cell adoptive immunotherapy: Coming of age
Baggio, L., Laureano, Á. M., Silla, L. M. D. R., & Lee, D. A. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.02.003 · Cited by 56
“NK cells may actually reduce GVHD by depleting recipient dendritic cells [32] and thereby eliminating antigen cross-presentation.”
BackgroundRey, J., Fauriat, C., Kochbati, E., Orlanducci, F., Charbonnier, A., D’Incan, E., Andre, P., Romagne, F., Barbarat, B., Vey, N., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00064 · Cited by 51
“NK cell importance in leukemia control has been evidenced by the pioneering study of Ruggeri and was followed since by many centers (8, 9).”
BackgroundEfficient and accurate KIR and HLA genotyping with massively parallel sequencing data
Song, L., Bai, G., Liu, X. S., Li, B., & Li, H. (2023) · Genome Research · doi:10.1101/gr.277585.122 · Cited by 61
Natural Killer Cell-Mediated Immunotherapy for Leukemia
Allison, M., Mathews, J., Gilliland, T. M., & Mathew, S. O. (2022) · Cancers · doi:10.3390/cancers14030843 · Cited by 57
“During adoptive transfer, NK cells are isolated from the peripheral blood, bone marrow, or umbilical cord from either a healthy donor (allogeneic) or the patient (autologous) [114].”
BackgroundRuppel, K. E., Fricke, S., Koehl, U., & Schmiedel, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.822298 · Cited by 56
“To this end, different immune cell types are tested, especially focusing on Natural Killer (NK) cells, as these immune cells, unlike T cells, do not cause graft versus host disease (GvHD), even if donor and recipient have an HLA mismatch (7).”
BackgroundChallenges to the broad application of allogeneic natural killer cell immunotherapy of cancer
Kennedy, P. R., Felices, M., & Miller, J. S. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02769-4 · Cited by 54
“Transfer of cytokine-activated autologous NK cells showed poor responses to metastatic cancers in early clinical trials [4, 5], whereas mismatched inhibitory receptors and ligands from allogeneic NK cells showed greater clinical responses in hematopoietic stem cell transplantation [6] and adoptive transfer of NK cells…”
BackgroundThe role of CD4+ T cells in tumor and chronic viral immune responses
Xie, L., Fang, J., Yu, J., Zhang, W., He, Z., Ye, L., & Wang, H. (2023) · MedComm · doi:10.1002/mco2.390 · Cited by 62
Metadata
- Authors
- Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M. F., & Velardi, A.
- Affiliations
- University of Perugia (IT)
- Yale University (US)
- Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy.
- Ospedale Policlinico San Martino (IT)
- ORCID
- Venue
- Science
- Published
- 2002-03-15
- Volume
- 295
- Issue
- 5562
- Pages
- 2097-2100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2147068163
- Cited by
- 3,380
- References
- 21
- Citations by year
- 2026: 46 · 2025: 92 · 2024: 112 · 2023: 134 · 2022: 157 · 2021: 156 · 2020: 139 · 2019: 155 · 2018: 140 · 2017: 157 · 2016: 152 · 2015: 171 · 2014: 134 · 2013: 162 · 2012: 150
- FWCI
- 63.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL03979)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- natural killer cells, NK cell alloreactivity, allogeneic hematopoietic stem cell transplantation, mismatched transplantation, graft-versus-host disease, graft rejection, leukemia relapse, T cell depletion, conditioning intensity, leukemia
- MeSH terms
- Acute Disease, Animals, Antigen-Presenting Cells, Graft Survival, Graft vs Host Disease, H-2 Antigens, Haplotypes, Histocompatibility Testing, Humans, Killer Cells, Natural, Leukemia, Myeloid, Mice, Inbred Strains, Receptors, Immunologic, Recurrence, T-Lymphocytes, Bone Marrow Transplantation, Mice, SCID, Mice, Inbred NOD, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning, Graft vs Leukemia Effect, Mice, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Receptors, KIR
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.